Medical Oncology and Tumor Pharmacotherapy

, Volume 4, Issue 3–4, pp 245–257 | Cite as

The iatrogenic leukaemias induced by radio-and/or chemotherapy

  • Y. Najean
Chemical Cancer Risks


A short review, limited to recently published series of data, has been compiled on the ‘therapy-induced’ secondary malignancies. Their frequency, peak of incidence, haematological and clinical criteria, the influence of age, treated primary disease, choice of drug(s) and modality of prescription and the role of genetic and environmental factors are analyzed. The risk varies between 0.6 and 20.5% after different treatment forms. Some suggestions for the choice of treatment of chronic malignant disorders, and for the design of future epidemiological studies are given.

Key words

Leukaemias Lymphomas Cancers Chemotherapy Radiotherapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Haddow A, Harris R, Kon G AR, Roe E MF: The growth-inhibitory and carcinogenetic properties of 4-amino-stilbene and derivatives.Trans Res Soc 241 247–252 (1948).Google Scholar
  2. 2.
    Rieche K: Carcinogenicity of antineoplastic in man.Cancer Treat Res 11, 29–67 (1984).Google Scholar
  3. 3.
    Committee for the compilation of materials on damage caused by the atomic bombs.Physical, Method and Social Effects of the Atomic Bombings. p. 706. New York, Basic Books (1979).Google Scholar
  4. 4.
    Kohn H I, Fry R J M: Radiation carcinogenesis.New Engl J Med 310, 506–511 (1984).Google Scholar
  5. 5.
    Tubiana M: Cancers par nuisances thérapeutiques: cancer et radiothérapie.Bull Cancer 70, 47–54 (1983).PubMedGoogle Scholar
  6. 6.
    Bookman M A, Longo D L: Concomitant illness in patients treated for Hodgkin's disease.Cancer Treat Rev 13, 77–111 (1986).PubMedCrossRefGoogle Scholar
  7. 7.
    Edwards F M: Dose-response models and methods of risk prediction and causation examination.Seminars Nucl Med 16, 118–130 (1986).CrossRefGoogle Scholar
  8. 8.
    Coleman C N, Kaplan H S, Cox R, Varghese A, Butterfield P, Rosenburg S A: Leukemias, non-Hodgkin's lymphomas and solid tumours in patients treated for Hodgkin's diseaseCancer Surv 1, 734–744 (1982).Google Scholar
  9. 9.
    Glicksman A S, Pajak T F, Gottlieb A, Nissen S, Stutzman L, Cooper M R: Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a cancer and leukemia group B study.Cancer Treat Rep 66, 1035–1044 (1982).PubMedGoogle Scholar
  10. 10.
    Grünwald H W, Rosner F: Acute myeloid leukemia following treatment of Hodgkin's disease. A reviewCancer 50, 676–683 (1982).PubMedCrossRefGoogle Scholar
  11. 11.
    Blayney D W, Longo D L, Young R Cet al.: Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease.New Engl J Med 316, 710–714 (1987).PubMedGoogle Scholar
  12. 12.
    Unger P F, Auclerc G, Weil M, Jacquillat C: Tumeurs solides après traitement pour maladie de Hodgkin.Presse Méd 10, 1463–1467 (1981).Google Scholar
  13. 13.
    Krause J R, Aynyang H Q, Ellis L D: Secondary non hematopoietic cancers arising following treatment of hematopoietic disorders.Cancer 55, 512–513 (1985).PubMedCrossRefGoogle Scholar
  14. 14.
    Valagussa P, Santoro A, Fassati F, Banfi A, Bonadonna G: Second acute leukemia and other malignancies following treatment for Hodgkin's disease.J clin Oncol 4, 830–837 (1986).PubMedGoogle Scholar
  15. 15.
    Moroff S V, Fuks J Z: Thyroid cancer following radiotherapy for Hodgkin's disease.Med ped Oncol 14, 216–220 (1986).CrossRefGoogle Scholar
  16. 16.
    Kinsella T J, Fraas B A, Glatstein G: Late effects of radiation therapy in the treatment of Hodgkin's disease.Cancer Treat Rep 66, 991–1001 (1982).PubMedGoogle Scholar
  17. 17.
    MacDougall I R, Coleman C R, Burks J S, Saunders W, Kaplan H S: Thyroid carcinoma after high dose external radiotherapy for Hodgkin's disease. Report of three cases.Cancer 45 2056–2060 (1980).CrossRefGoogle Scholar
  18. 18.
    Henry-Amar M: Second cancers after radiotherapy and chemotherapy of early stages of Hodgkin's disease.J natn Cancer Inst 71, 911–916 (1983).Google Scholar
  19. 19.
    Koletsky A J, Bertins J R, Farber L Ret al.: Second neoplasms in patients with Hodgkin's disease following combined modality therapy: the Yale experience.J clin Oncol 4, 311–317 (1986).PubMedGoogle Scholar
  20. 20.
    Canellos G P, Come S. E, Skarin A T: Chemotherapy in the treatment of Hodgkin's disease.Seminars Hemat 20, 1–24 (1983).Google Scholar
  21. 21.
    Boivin J F, Hutchison G B, Lydon M, Godbold J, Clivrosh J, Schottenfeld D: Second primary cancers following treatment of Hodgkin's disease.J nat Cancer Inst 72, 223–241 (1984).Google Scholar
  22. 22.
    Coltman C A, Dixon D O: Second malignancies complicating Hodgkin's disease: a Southwest oncology group 10-year follow-up.Cancer Treat Rep 66, 1023–1033 (1982).PubMedGoogle Scholar
  23. 23.
    Nelson D F, Cooper S, Weston M G, Rubin P: Second malignant neoplasms in patient treated for Hodgkin's disease with radiotherapy or radiotherapy and chemotherapy.Cancer 48, 2386–2393 (1981).PubMedCrossRefGoogle Scholar
  24. 24.
    Jacquillat C, Khayat D, Desprez-Curely J Pet al.: Non-Hodgkin's lymphoma occurring after Hodgkin's disease.Cancer 53, 359–462 (1986)Google Scholar
  25. 25.
    Wahlin A, Roos G, Rudolphi O, Holm J: Melphalan related leukemia in multiple myeloma.Acta med Scand 211, 203–208 (1982).PubMedGoogle Scholar
  26. 26.
    Bergsagel D G, Bailey A J, Lanagley G R, Mac-Donald R N, White D F, Miller A B: The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia.New Engl J Med 301, 743–747 (1979).PubMedGoogle Scholar
  27. 27.
    Berk P D, Goldberg J D, Silverstein M Net al: Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.New Engl J Med 304, 441–447 (1981).PubMedGoogle Scholar
  28. 28.
    Haanen G, Mathé G, Hayat M: Treatment of polycythemia vera by radio-phosphorus or busulphan: a randomized trial.Br J Cancer 44, 75–80 (1981).Google Scholar
  29. 29.
    Landaw S A: Acute leukemia in polycythemia vera.Seminars Hemat 23, 156–165 (1986).Google Scholar
  30. 30.
    Najean Y, Deschamps A, Dresch C, Daniel M T, Rain J D, Arrago J P: Acute leukemia in polycythemia vera. A clinical study of 33 cases among 298 patients with long-term follow-up.Cancer, in press.Google Scholar
  31. 31.
    Brusamolino E, Salvaneschi L, Canevari A, Bernasconi C: Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia.J clin Oncol 2, 558–561 (1984).PubMedGoogle Scholar
  32. 32.
    Bellucci S, Janvier M, Tobelem Get al.: Essential thrombocythemias. Clinical, evolutionary and biological data.Cancer 58, 2440–2447 (1986).PubMedCrossRefGoogle Scholar
  33. 33.
    Auclerc G, Jacquillat C, Auclerc M F, Weil M, Bernard J: Post-therapeutic acute leukemia.Cancer 44, 2017–1025 (1979).PubMedCrossRefGoogle Scholar
  34. 34.
    Chastang C L, Binet J L: Preliminary results of the French cooperative group for the study of chronic lymphocytic leukemia. Unpublished data.Google Scholar
  35. 35.
    Osgood E E: Contrasting evidence of acute leukemia in32P-treated patients with polycythemia vera and chronic lymphocytic leukemia.J Lab Clin Med 64, 243–256 (1964).Google Scholar
  36. 36.
    Greene M H, Harris E L, Gershenson D Met al.: Melphalan may be a more potent leukemogen than cyclophosphamide.Ann Int Med 105, 360–367 (1986).PubMedGoogle Scholar
  37. 37.
    Smith P G: Late effects of X-ray treatment of ankylosing spondilytis, in Boice J D, Fraumeri J F (eds):Radiation Carcinogenesis, pp. 107–118 (1984).Google Scholar
  38. 38.
    Baltus J A M, Boersmo J W, Hartman A P, Vandembroucke J P: The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclosphosphamide.Ann Rheum Dis 42, 268–373 (1983).CrossRefGoogle Scholar
  39. 39.
    Editorial: Lymphoma in organ transplant recipients.Lancet 1, 601–604 (1986).Google Scholar
  40. 40.
    Penn I: Malignancies following the use of cyclosporin A in man.Cancer Surv 1, 621–624 (1982).Google Scholar
  41. 41.
    Linos A, Gray J E, Orvis A L, Kyle R A, O'Fallon W M, Kurland L T: Low-dose radiation and leukemia.New Engl J Med 302, 1101–1105 (1980).PubMedGoogle Scholar
  42. 42.
    Webster E W: On the question of cancer induction by small X-ray doses.Am J Roentgenol 137, 647–666 (1981).Google Scholar
  43. 43.
    Boopalam N, Price K S, Norgello H, Fried W: Busulfan induced suppression of natural killer cell activity.Exp Hemat 13, 1127–1132 (1985).Google Scholar
  44. 44.
    Romau E, Beral V, Carpenter L: Childhood leukaemia in relation to nuclear establishments in the vicinity.Br Med J 294, 597–603 (1987).CrossRefGoogle Scholar
  45. 45.
    Boice J D: Cancer following medical irradiation.Cancer 47, 1081–1090 (1981).PubMedCrossRefGoogle Scholar
  46. 46.
    Weiss R B, Issell B F: The nitroso-ureas.Cancer Treat Rev 9, 313–330 (1982).PubMedCrossRefGoogle Scholar
  47. 47.
    Willkens R F, Watson M A: Methotrexate: a perspective of its use in the treatment of rheumatic diseases.J Lab Clin Med 100, 314–321 (1982).PubMedGoogle Scholar
  48. 48.
    Weinstein A, Marlowe S, Korn J, Faronhar F: Low-dose methotrexate treatment of rheumatoid arthritis.Am J Med 79, 331–337 (1985).PubMedCrossRefGoogle Scholar
  49. 49.
    Koeffler H P: Myelodysplastic syndromes (preleukemia).Seminars Hemat 23, 284–299 (1986).Google Scholar
  50. 50.
    Penn I: Mechanisms of therapy-induced malignancies.Cancer Surv 1, 764–782 (1982).Google Scholar
  51. 51.
    Arcy P F d', Griffin J P: Drug induced cancers in animals and man.Cancer Surv 1, 633–680 (1982).Google Scholar
  52. 52.
    Hoover R, Fraumeni J F: Drug induced cancer.Cancer 47, 1071–1080 (1981).PubMedCrossRefGoogle Scholar
  53. 53.
    Strong L C, Williams W R: The genetic implications of long-term survival of childhood cancer.Am J Ped Hemat/Oncol 9, 99–103 (1987).CrossRefGoogle Scholar
  54. 54.
    Pedersen J, Philip P, Pederson N Tet al.: Acute non-lymphocytic leukemia, pre-leukemia and acute myelo-proliferative syndrome secondary to treatment of other malignant diseases.Cancer 54, 452–462 (1984).PubMedCrossRefGoogle Scholar
  55. 55.
    Jacobs A: Human pre-leukemia: do we have a model?Br J Cancer 55, 1–5 (1987).PubMedGoogle Scholar
  56. 56.
    Gramont A de, Louvet C, Krulik Met al.: Preleukemic changes in cases of non-lymphocytic leukemia secondary to cytotoxic therapy.Cancer 58, 630–634 (1986).PubMedCrossRefGoogle Scholar
  57. 57.
    Foucar K, Mac Kenna R W, Bloomfield C J, Bowers T K, Brunning R D: Therapy-related leukemia. A panmyelosis.Cancer 43, 1285–1296 (1979).PubMedCrossRefGoogle Scholar
  58. 58.
    Anderson R L, Bagby G C, Richert-Boe K, Magenis R E, Koler R D: Therapy related pre-leukemic syndrome.Cancer 47, 1867–1871 (1981).PubMedCrossRefGoogle Scholar
  59. 59.
    Mac Kenna R W, Parkin J L, Foucar K, Brunning R D: Ultra-structural characteristics of therapy related acute non-lymphocytic leukemia.Cancer 48, 725–737 (1981).CrossRefGoogle Scholar
  60. 60.
    Bennett J M, Catovsky D, Daniel M Tet al.: Proposals for the classification of the myelodysplastic syndromes.Br J Haemat 51, 189–195 (1982).Google Scholar
  61. 61.
    Vardinman J W, Coelho A, Golomb H M, Rowley J: Morphologic and cytochemical observations on the overt leukemic phase of therapy related luekemia.Am J Clin Path 79, 525–530 (1983).Google Scholar
  62. 62.
    Prchal J T, Throckmorton D W, Carroll A J, Fuson E W, Gams R A, Prchal J S: A common progenitor for human myeloid cells.Nature 276, 590–592 (1978).CrossRefGoogle Scholar
  63. 63.
    Failkow P V: Clonal development, heterogeneity and multistep pathogenesis of human leukemia, in Gale R P, Golde D W (eds):Leukemia: Recent Advances in Biology and Treatment, p. 491. New York, Alan Liss (1985).Google Scholar
  64. 64.
    Berger R, Bernheim A, Daniel M T, Valensi F, Flandrin G: Leucémies induites. Aspects cytogénétique et cytologique.Nouv Revue fr Hémat 23, 275–284 (1981).Google Scholar
  65. 65.
    Pedersen-Bjergaad J: Incidence, previous treatment and chromosome characteristics of secondary acute non-lymphocytic leukemia.Cancer Treat Rev 12, 65–75 (1985).CrossRefGoogle Scholar
  66. 66.
    Rowley J D, Golomb H M, Vardiman J W: Non-random chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant diseases.Blood 58, 759–767 (1981).PubMedGoogle Scholar
  67. 67.
    Le Beau M N, Westbrosk C A, Diaz M Oet al.: Evidence for the involvement of GM-CSF andfms in the deletion 5 q in myeloid disorders.Science 231, 984–987 (1986).PubMedCrossRefGoogle Scholar
  68. 68.
    Donovan P B, Landaw S A, Dresch Cet al.: Resistance to therapy of acute leukemia developing in the course of polycythemia vera.Nouv Revue fr Hémat 23, 178–192 (1981).Google Scholar
  69. 69.
    Kinjsley E C, Durie B G M: Prolonged survival in patients with treatment related leukemia.Scand J Haemat 37, 103–105 (1986).Google Scholar
  70. 70.
    Vaughan W P, Karp J E, Burke P J: Effective chemotherapy of acute myelocytic leukemia occurring after alkylating agent or radiation therapy for prior malignancy.J clin Oncol 1, 204–207 (1983).PubMedGoogle Scholar
  71. 71.
    Chomienne C, Najean Y, Degos L, Thomas G: Present results of the treatment of myelodysplastic syndromes with low-dose cytosine-arabinoside.Acta Haemat, in press.Google Scholar
  72. 72.
    Gold E J, Mertelsmann R H, Itri L Met al.: Phase I clinical trial of 13 cis-retinoic acid in myelodysplastic syndromes.Cancer Treat Rep 67, 981–987 (1983).PubMedGoogle Scholar
  73. 73.
    Greenberg B R, Durie B G M, Barnett T C, Meyskens, F L: Phase I–II study of 13-cis retinoic acid in myelodysplastic syndrome.Cancer Treat Rep 69, 1369–1374 (1985).PubMedGoogle Scholar
  74. 74.
    Appelbaum F R Storb R, Ramberg R Eet al.: Treatment of preleukemic syndromes with marrow transplantation.Blood 69, 92–96 (1987).PubMedGoogle Scholar
  75. 75.
    Rubin P, Zagars G, Chuang C, Thomas E M: Hodgkin's disease: is there a price for successful treatment?Int J Radiat Oncol 12, 153–166 (1986).CrossRefGoogle Scholar
  76. 76.
    Cornbleet M A, Vitolo V, Ultmann J C: Pathologic stages I A and III A Hodgkin's disease: results of treatment with radio-therapy alone.J clin Oncol 3, 758–768 (1985).PubMedGoogle Scholar

Copyright information

© Pergamon Press Ltd. 1987

Authors and Affiliations

  • Y. Najean
    • 1
  1. 1.Department of Nuclear Medicine and HaematologySt Louis HospitalParisFrance

Personalised recommendations